Human TIGIT Stable Cell Line-CHO-K1

Myelodysplastic syndrome (MDS) comprises heterogeneous blood disorders, originating from abnormal hematopoietic stem cells. It features peripheral blood (PB) cytopenia, bone marrow (BM)dysfunctional hematopoiesis, and increased AML risk. Researchers aimed to investigate the role of TIGIT in myelodysplastic syndrome (MDS) and its potential as a therapeutic target. They obtained fresh PB and BM samples from MDS patients and healthy donors, analyzing TIGIT expression on NK and T cells using flow cytometry (FCM) and PCR. Results showed high TIGIT expression on PB NK and T cells, correlating with disease progression and immune evasion in MDS. Functional assays revealed impaired NK and T cell activity associated with elevated TIGIT levels. Notably, blocking TIGIT enhanced antitumor effects, suggesting its potential as a therapeutic target in MDS.

Figure 1. The function of NK and T cells is limited by TIGIT. Cytokine expression and proliferation of TIGIT+ and TIGIT– NK and T cells were assessed in HDs. (Meng F, et al., 2020)

Utilizing Creative Biogene's Human TIGIT Stable CHO Cell Line enhances experiments related to TIGIT function. This stable cell line offers a consistent and reliable cellular model for investigating TIGIT-mediated immune regulation. By using this cell line, researchers can streamline experimental procedures, reduce variability, and achieve reproducible results in studies focused on TIGIT's impact on NK and T cell function, cytokine expression, and proliferation.